Agents for the treatment of heparin-induced thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 24, Issue 4, 2010, Pages 755-775

  Warkentin, Theodore E ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Argatroban; Coumarin necrosis; Danaparoid; Fondaparinux; Heparin induced thrombocytopenia; Hirudin

Indexed keywords

ACENOCOUMAROL; ANTITHROMBIN III; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; IPRIVASK; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PROTEIN C; RECOMBINANT HIRUDIN; REVASK; THROMBIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOPATHOGENESIS; INTERNATIONAL NORMALIZED RATIO; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 77955119891     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.05.009     Document Type: Review

References (76)

1. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101(5):502-507.
2. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005, 94(1):132-135.
3. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126(Suppl 3):311S-337.
4. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):340S-380.
5. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106(6):629-635.
6. Warkentin T.E., Elavathil L.J., Hayward C.P.M., et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127(9):804-812.
7. Chong B.H., Magnani H.N. Danaparoid for the treatment of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 319-343. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
8. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 345-378. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
9. Lewis B.E., Hursting M.J. Argatroban therapy in heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 379-408. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
10. Bartholomew J.R. Bivalirudin for the treatment of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 409-439. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
11. Bradner J.E., Eikelboom J.W. Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inhibitors. Heparin-induced thrombocytopenia 2007, 441-461. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
12. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121(4):535-555.
13. Warkentin T.E., Makris M., Jay R.M., et al. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008, 121(7):632-636.
14. Jay R.M., Warkentin T.E. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT?. J Thromb Haemost 2008, 6(9):1598-1600.
15. Pruthi R.K., Daniels P.R., Nambudiri G.S., et al. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT?. J Thromb Haemost 2009, 7(3):499-501.
16. Warkentin T.E., Sheppard J.I. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006, 20(4):259-272.
17. Greinacher A., Juhl D., Strobel U., et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5(8):1666-1673.
18. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008, 6(8):1304-1312.
19. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344(17):1286-1292.
20. Fausett M.B., Vogtlander M., Lee R.M., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001, 185(1):148-152.
21. Greer I.A., Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106(2):401-407.
22. Warkentin T.E., Sheppard J.I., Siguoin C.S., et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006, 108(9):2937-2941.
23. Warkentin T.E., Greinacher A., Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?. Ann Thorac Surg 2009, 87(5):1633-1640.
24. Greinacher A., Alban S., Omer-Adam M.A., et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008, 122(2):211-220.
25. Warkentin T.E., Cook R.J., Marder V., et al. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010, 8(3):504-512.
26. Lubenow N., Hinz P., Thomaschewski S., et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010, 115(9):1797-1803.
27. Kelton J.G., Sheridan D., Santos A., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988, 72(3):925-930.
28. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992, 68(1):95-96.
29. Greinacher A., Pötzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994, 71(2):247-251.
30. Suh J.S., Aster R.H., Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin:platelet factor 4. Blood 1998, 91(3):916-922.
31. Greinacher A., Gopinadhan M., Guenther J.U., et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006, 26(10):2386-2393.
32. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332(20):1330-1335.
33. Warkentin T.E., Roberts R.S., Hirsh J., et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003, 163(20):2518-2524.
34. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106(12):3791-3796.
35. Warkentin T.E. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004, 30(3):273-283.
36. Warkentin T.E., Hayward C.P.M., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84(11):3691-3699.
37. Arepally G.M., Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001, 98(4):1252-1254.
38. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 21-66. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
39. Greinacher A., Kohlmann T., Strobel U., et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009, 113(20):4970-4976.
40. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009, 113(20):4963-4969.
41. Warkentin T.E., Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001, 135(7):502-506.
42. Rice L., Attisha W.K., Drexler A., et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002, 136(3):210-215.
43. Warkentin T.E., Bernstein R.A. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003, 348(11):1067-1069.
44. Warkentin T.E. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004, 110(18):e454-e458.
45. Srinivasan A.F., Rice L., Bartholomew J.R., et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004, 164(1):66-70.
46. Smythe M.A., Warkentin T.E., Stephens J.L., et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002, 71(1):50-52.
47. Warkentin T.E. Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. J Thromb Haemost 2006, 4(4):894-896.
48. Warkentin T.E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996, 10(4):249-258.
49. Warkentin T.E. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001, 135(8 pt 1):589-593.
50. Warkentin T.E. Heparin-induced thrombocytopenia. Hemostasis and thrombosis: basic principles and clinical practice 2006, 1649-1661. Lippincott Williams & Wilkins, Philadelphia. 5th edition. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
51. Greinacher A., Warkentin T.E. Treatment of heparin-induced thrombocytopenia: an overview. Heparin-induced thrombocytopenia 2007, 283-317. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
52. Prechel M.M., McDonald M.K., Jeske W.P., et al. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005, 3(10):2168-2175.
53. Socher I., Kroll H., Jorks S., et al. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J Thromb Haemost 2008, 6(1):197-200.
54. Newman P.M., Chong B.H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000, 96(1):182-187.
55. Greinacher A., Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 2008, 99(5):819-829.
56. Krauel K., Fürll B., Warkentin T.E., et al. Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of PF4/heparin complexes. J Thromb Haemost 2008, 6(12):2160-2167.
57. Prechel M., Jeske W.P., McDonald M.K., et al. Desulfated heparin blocks platelet activation induced by HIT antibodies/heparin. A new approach to patient management [abstract]. Blood 2004, 104(11 Pt 1 of 2):827.
58. Chong B.H., Gallus A.S., Cade J.F., et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 2001, 86(5):1170-1175.
59. Lubenow N., Warkentin T.E., Greinacher A., et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006, 117(5):507-515.
60. Farner B., Eichler P., Kroll H., et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001, 85(6):950-957.
61. Demers C., Ginsberg J.S., Brill-Edwards P., et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991, 78(9):2194-2197.
62. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356(25):2653-2654.
63. Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia. Thromb Haemost 2008, 99(4):779-781.
64. Salem M, Elrefai S, Shrit MA, et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by catastrophic stroke. Thromb Haemost 2010, in press.
65. Kuo K.H.M., Kovacs M.J. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005, 93(5):999-1000.
66. Lobo B., Finch C., Howard A., et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008, 99(1):208-214.
67. Grouzi E, Kyriakou E, Panagou I, et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2009. [Epub ahead of print].
68. Hacquard M., De Maistre E., Lecompte T. Lepirudin: is the approved dosing schedule too high?. J Thromb Haemost 2005, 3(11):2593-2596.
69. Lubenow N., Eichler P., Lietz T., et al. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005, 3(11):2428-2436.
70. Lubenow N., Eichler P., Lietz T., et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004, 104(10):3072-3077.
71. Tardy B., Lecompte T., Boelhen F., et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006, 108(5):1492-1496.
72. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103(14):1838-1843.
73. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163(15):1849-1856.
74. Lewis B.E., Wallis D.E., Hursting M.J., et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006, 129(6):1407-1416.
75. Warkentin T.E., Greinacher A., Craven S., et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005, 94(5):958-964.
76. Kaiser T.H., Fish D.N. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006, 26(4):452-460.